Rafferty Asset Management
ZVRA icon

Rafferty Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Rafferty Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,920
Closed -$143K – 1148
2025
Q4 		$143K Buy
15,920
+4,041
+34% +$38.2K ﹤0.01% 1118
2025
Q3 		$113K Buy
+11,879
New +$119K ﹤0.01% 1096

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Rafferty Asset Management's ZVRA Position: Q1 2026 in Review

Rafferty Asset Management sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 15,920 shares — an estimated $143K sold.

Rafferty Asset Management first reported a position in ZVRA in Q3 2025 and held it in 2 quarters. The position peaked at $143K in Q4 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Rafferty Asset Management reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Rafferty Asset Management sold 15,920 Zevra Therapeutics shares in Q1 2026, an estimated $143K.
  • Rafferty Asset Management first reported a position in Zevra Therapeutics in Q3 2025 and held it in 2 quarters.
  • Rafferty Asset Management's Zevra Therapeutics position peaked at $143K in Q4 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.